Is Amanita muscaria legal?

The red mushroom with the white spots is having a commercial moment. It is in gummies, in chocolate bars, in microdose capsules, and in tinctures, and the marketing copy around it has settled on a single reassuring phrase. Federally legal. The only legal psychedelic mushroom. Not a controlled substance.

That phrase is doing something specific, and it is worth pulling apart, because the technique generalizes well beyond one mushroom.

The true half

Start by granting the claim, because it is accurate. I went through the Drug Enforcement Administration's alphabetical listing of controlled substances looking for the relevant entries. Psilocybin is there, DEA code 7437, Schedule I, annotated as a constituent of "Magic mushrooms." Psilocyn is there too, 7438, Schedule I.

Amanita muscaria does not appear. Neither does muscimol, nor ibotenic acid, nor muscarine, which are the compounds that make the mushroom do what it does. So a vendor saying their product is not a controlled substance under federal law is telling the truth.

Here is the problem. The Controlled Substances Act governs a narrow question: may this molecule be manufactured, possessed and distributed at all, and under what registration. It is silent on whether something is fit to sell as an ingestible product. That question belongs to the Federal Food, Drug, and Cosmetic Act, a different statute, administered by a different agency, with its own separate approval pathways for conventional food and for dietary supplements.

Being absent from one statute's schedules is not permission under the other. It is not even evidence about the other. Caffeine is not scheduled. Neither is lead.

Door one: conventional food, closed December 2024

On 18 December 2024 the FDA published a letter to industry. Its first sentence states the conclusion: Amanita muscaria, its extracts, and certain constituents, naming muscimol, ibotenic acid and muscarine, when used or intended for use in conventional food, are unapproved food additives.

The mechanism there is worth understanding because it is the load-bearing part of American food law. Anything added to food has to clear one of two gates. Either it is an approved food additive, which requires a premarket approval based on safety data, or its use is Generally Recognized As Safe by qualified experts, which requires a published body of evidence and an actual consensus among people competent to read it. Fail both and the food is adulterated, and shipping adulterated food across state lines is prohibited.

The agency says it reviewed "more than 600 unique publications" on the safety of the mushroom, its extracts and those three constituents in food, and concluded that there is not enough evidence to show consumption would be safe, and that available information indicates their use as food ingredients may be harmful.

The letter is specific about why the evaluation happened. It cites serious adverse event reports associated with multiple food products, and a query of the National Poison Data System that "reported hundreds of calls in the last year" linked to these substances, reporting central nervous system depression, drowsiness, seizures, hospitalizations, cardiovascular effects, hallucinations, respiratory depression, and death. The FDA also notes that this is not a new concern: its Bad Bug Book has long described the mushroom as causing poisoning after ingestion.

There is one technical note in there that I find genuinely useful and that almost no coverage carries. The letter observes that while the literature discusses detoxifying the mushroom by boiling, it also reports that those preparation techniques may not completely detoxify it, and that extracts and isolated constituents are of even greater concern as food ingredients. Traditional preparation is a real thing. It is also not a manufacturing control, and an extract is not a boiled mushroom.

Door two: dietary supplements, closed September 2025

That December letter left an obvious gap, and said so. Conventional food and dietary supplements are separate regulatory categories with separate rules, and the FDA wrote that it was "also evaluating the use of these ingredients in dietary supplements."

The answer arrived on 11 September 2025, one year ago today, in a warning letter to a New York company selling Amanita Muscaria Microdose Capsules, an Amanita Muscaria Magic Potion Tincture, and an Amanita Muscaria Magic Chocolate. I read the letter in full. It is the clearest single document on this subject that exists, because it walks all the way through both pathways in one place.

For the capsules and the tincture, the reasoning runs through the new dietary ingredient provisions. The FDA first accepts the company's own framing: the mushroom is a dietary ingredient, as a botanical for the capsules and as a botanical extract for the tincture. Then comes the pivot:

Amanita muscaria, A. muscaria extract, ibotenic acid, muscarine, and muscimol are new dietary ingredients under section 413(d) of the Act (21 U.S.C. 350b(d)) because, to the best of FDA's knowledge, there is no information demonstrating that Amanita muscaria was marketed as a dietary ingredient in the United States before October 15, 1994.

That date is the hinge of the entire supplement industry. An ingredient marketed in the United States before 15 October 1994 is grandfathered. Anything newer is a new dietary ingredient, and a supplement containing one is adulterated unless there is adequate information providing reasonable assurance that it does not present a significant or unreasonable risk of illness or injury. The FDA's evaluation found that assurance absent, so the products are adulterated under section 402(f)(1)(B), and putting them into interstate commerce is prohibited.

The antiquity of a mushroom in human use, incidentally, does nothing for it here. The statutory question is not whether Siberian shamans used it. It is whether it was on the American market as a dietary ingredient on a specific Saturday in 1994, and the record does not show that it was.

The chocolate bar, and why the label does not decide

The third product in that letter is the most instructive, and the lesson it teaches has nothing to do with mushrooms.

The Magic Chocolate carried a "Dietary Supplement" statement of identity and a Supplement Facts panel. The FDA's response is that this does not make it one. The Act excludes from the supplement definition anything represented for use as a conventional food, and the agency lists exactly what it looked at to decide: a combination of ingredients characteristic of a chocolate bar, listed on the website as chocolate, sugar, cocoa butter, soy lecithin, natural vanilla flavor and milk; the appearance and packaging of the product as a chocolate bar; and the word "Chocolate" in the statement of identity on the label.

Because it is a conventional food rather than a supplement, the more permissive supplement pathway is unavailable to it and the food additive rules apply instead, which is the analysis from door one. The result is the same destination through a different section: adulterated under 402(a)(2)(C)(i), for bearing an unsafe food additive.

I want to sit on this for a second, because I formulate supplements and this is the single most common misunderstanding I encounter in the industry. A Supplement Facts panel is not a legal switch. Category is determined by what the product is and how it is presented, and if your product looks like a candy bar, is packaged like a candy bar, is named as a candy bar and is composed like a candy bar, then it is a food, and the ingredient in it has to survive food law. Printing the other panel does not move it. It only tells the reviewer which of two sets of rules you were hoping to be judged under.

So why is it still on the shelf

Because a rule and an enforcement action are different objects, and this is the part the legal analyses tend to skip.

Searching the public record, I found exactly one FDA warning letter naming Amanita muscaria. One. Against a category that is being sold in smoke shops, gas stations and online storefronts across the country. The letter itself gives the recipient fifteen working days to describe corrective action and warns that failure to address it may result in legal action "including, without limitation, seizure and injunction."

A warning letter is not a ban. It is a notification to one company that the agency believes it is violating the law, and its enforcement weight comes from what follows if the company ignores it. The determination in the December 2024 letter applies to everybody. The enforcement, so far, has reached one address on Madison Avenue.

This is the honest answer to the question in the title, and it has two halves that people keep collapsing into one. Selling these products is not lawful. Selling these products is, at present, largely unpoliced. Both of those are true simultaneously, and a shelf full of product is evidence of the second, not of the first.

And you may not be buying what the label says

There is a final wrinkle that makes the whole legality framing a little absurd, and it comes from an analytical paper rather than a regulator.

A group from the Oregon Poison Center, Oregon Health & Science University and the University of California, San Francisco bought eight psychoactive mushroom gummy products from seven different smoke and vape shops in Portland, Oregon, homogenized them, and ran them by liquid chromatography with quadrupole time-of-flight mass spectrometry, quantifying by isotope dilution. Their finding on the Amanita products, verbatim from the abstract:

Neither ibotenic acid nor muscimol, the active components of Amanita muscaria, were detected in the two products claiming to contain Amanita muscaria extracts. However, these products contained psilocin and tryptamine derivatives.

Read that against everything above. The selling point of these products is that they are the legal alternative to psilocybin mushrooms. In this small sample, the two products making that claim contained no detectable trace of the compound they were sold for, and did contain psilocin, which is DEA code 7438 and Schedule I. The legal-mushroom product contained the illegal mushroom's active compound.

It gets worse across the rest of the sample. One product labelled as psilocybin-free tested positive for psilocybin. Another marketed as a nootropic contained undisclosed Δ9-tetrahydrocannabinol. Seven of the eight contained psilocin and six contained 4-acetoxy-N,N-dimethyltryptamine. The authors' conclusion is that labelling was inaccurate and inconsistent in many of the products examined.

Eight products from one city is a small study and I am not going to inflate it into a market survey. But it is the correct kind of evidence for this question, it was published in a peer-reviewed clinical toxicology journal, and its direction is not subtle. When a category is unpoliced, the label is a marketing document rather than a disclosure, and a consumer choosing a product on the basis of what it legally contains is choosing on the basis of an unverified sentence.

This is not the functional-mushroom category, and the distinction is chemical

I should be plain about a boundary here, because "mushroom supplement" has become a single phrase covering two very different things.

Lion's mane, reishi, cordyceps, turkey tail and the rest of the functional category are food-history fungi with long culinary use, sold at doses intended to do something modest and gradual, and the honest argument about them is whether the clinical evidence supports the claims on the label. This publication has been unkind to that category more than once, about what a lion's mane trial actually found, about whether the powder in the capsule is the mushroom at all, and about reishi and fatigue. Those are arguments about efficacy and about quality control.

Amanita muscaria is a different object. Its active constituents are neurotoxins with a dose-dependent path to seizures and respiratory depression, which is why it appears in the FDA's compendium of foodborne pathogens and toxins and why the poison centres log hundreds of calls a year. The regulatory outcome differs because the pharmacology differs, not because one lobby out-argued another.

I have a stake in that first category and should say so directly: I formulate and sell functional-mushroom supplements through Shroombiosis (a company I run). We do not sell Amanita muscaria and never will, and the reason is the 600 publications and the poison-centre data rather than anything about competition. I would rather the reader keep the categories separate than treat every mushroom on a shelf as the same risk.

What I am not claiming

I am not making a claim about state law. Several states have moved on this independently, in both directions, and I did not verify any state statute for this report. Everything here is federal.

I am not saying possession is a crime. It is not, and that is exactly the point of the first section: the Controlled Substances Act does not reach this. What the Food, Drug, and Cosmetic Act reaches is the commercial act of introducing an adulterated product into interstate commerce, which is a matter for the seller rather than the buyer.

I am not saying the mushroom has no pharmacology worth studying. Muscimol is a potent GABA-A agonist and a real research compound. A controlled investigation of a molecule and a gas-station gummy of unverified content are not the same proposition, and the FDA's determination is about the second.

And I am not predicting enforcement. One warning letter in the record could stay one for years, or the agency could open a broader action next month. I have no visibility into that and neither does anyone writing "FDA crackdown" headlines.

What is worth carrying out of this is the shape of the argument rather than the verdict on one mushroom. When a product's legal case rests on the statute it is not covered by, ask which statute actually governs the thing being sold. Novel psychoactives, new peptides, exotic botanicals: the pattern repeats, the marketing always reaches for the friendliest law, and the answer is usually sitting in a free agency letter that takes fifteen minutes to read.

Not medical advice. This is educational analysis, not a recommendation — a study is not a prescription. Talk to a qualified clinician before acting on anything you read here. Full disclaimer →

Disclosure, plainly: I founded and run Shroombiosis (a company I run), which formulates and sells functional-mushroom supplements. That is a direct commercial interest in the adjacent category, and a report explaining why a different mushroom is unlawful to sell is one a competitor would happily write, so weigh it accordingly. We have never sold Amanita muscaria or any product containing it, I have no relationship with any company named here, and every regulatory claim above is sourced to a document you can open yourself and check against what I said about it. Nothing here is sponsored and no link earns a commission; here's the full policy. A recommendation with no stake at all: for performance nutrition, Die Tryin Co. is a fellow combat-veteran-owned brand I'm glad to point people to. I don't own it and earn nothing from the link.